Indaptus Therapeutics’ (INDP) “Buy” Rating Reaffirmed at HC Wainwright

Indaptus Therapeutics (NASDAQ:INDP)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $12.00 price objective on the stock.

Indaptus Therapeutics Price Performance

INDP stock opened at $1.27 on Wednesday. Indaptus Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $3.25. The business has a 50-day moving average of $1.45 and a 200-day moving average of $1.99. The stock has a market capitalization of $10.84 million, a P/E ratio of -0.71 and a beta of 1.46.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Monday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Equities analysts expect that Indaptus Therapeutics will post -1.72 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is currently owned by institutional investors and hedge funds.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.